Literature DB >> 21643961

The effect of selegiline on total scavenger capacity and liver fat content: a preliminary study in an animal model.

Gabor Bekesi1, Zsolt Tulassay, Gabriella Lengyel, Zsuzsa Schaff, Dezso Szombath, Julia Stark, Istvan Marczell, Peter Nagy-Repas, Ildiko Adler, Elek Dinya, Karoly Racz, Kalman Magyar.   

Abstract

Selegiline is a selective irreversible inhibitor of the B-type of monoamine oxidase (MAO-B). The spectrum of its pharmacological activity is wide, possesses antioxidant, antiapoptotic and neuroprotective properties and, additionally, we found it is effective on the total scavenger capacity (TSC), and the regulation of fat content in rat liver kept on lipid-rich diet. Our aim was to clarify whether the oral treatment with selegiline is protective on oxidative damage of Sprague-Dawley adult rats in vivo. Four groups of rats (five animals in a group) were examined: (1) lipid-rich diet, (2) normal rat food, (3) lipid-rich diet + selegiline and (4) normal rat food + selegiline. Selegiline solution (2.5 µg/ml) was supplied with the drinking water, which was freely available for the animals. Regarding the drinking habit of the rats (20-30 ml/day), the daily dose was roughly equal with that used in the human therapy (5-10 mg/day). TSC was determined both at the beginning (0 day) and at the end of the study (28 days), when the blood samples were taken for chemiluminometric assay. Fat content of the liver was determined in the freshly frozen tissue by Sudan staining. TSC was increased in both the selegiline-treated groups. Selegiline treatment prevented the increase of liver fat in the group fed with lipid-rich diet. Our results led us to the conclusion that prolonged selegiline administration can raise the antioxidant capacity of the animals and prevents the accumulation of fat in their livers.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21643961     DOI: 10.1007/s00702-011-0666-x

Source DB:  PubMed          Journal:  J Neural Transm (Vienna)        ISSN: 0300-9564            Impact factor:   3.575


  34 in total

1.  The potentiation of the anti akinetic effect after L-dopa treatment by an inhibitor of MAO-B, Deprenil.

Authors:  W Birkmayer; P Riederer; M B Youdim; W Linauer
Journal:  J Neural Transm       Date:  1975       Impact factor: 3.575

2.  R-deprenyl: pharmacological spectrum of its activity.

Authors:  K Magyar; B Szende; V Jenei; T Tábi; M Pálfi; E Szöko
Journal:  Neurochem Res       Date:  2010-08-20       Impact factor: 3.996

3.  (-) deprenyl induces activities of both superoxide dismutase and catalase but not of glutathione peroxidase in the striatum of young male rats.

Authors:  M C Carrillo; S Kanai; M Nokubo; K Kitani
Journal:  Life Sci       Date:  1991       Impact factor: 5.037

4.  Monoamine oxidase activity and monoamine metabolism in brains of parkinsonian patients treated with l-deprenyl.

Authors:  P Riederer; M B Youdim
Journal:  J Neurochem       Date:  1986-05       Impact factor: 5.372

5.  Some puzzling pharmacological effects of monoamine oxidase inhibitors.

Authors:  J Knoll; K Magyar
Journal:  Adv Biochem Psychopharmacol       Date:  1972

6.  The anti-Parkinson drug rasagiline and its cholinesterase inhibitor derivatives exert neuroprotection unrelated to MAO inhibition in cell culture and in vivo.

Authors:  M B Youdim; A Wadia; W Tatton; M Weinstock
Journal:  Ann N Y Acad Sci       Date:  2001-06       Impact factor: 5.691

Review 7.  (-)-Deprenyl reduces neuronal apoptosis and facilitates neuronal outgrowth by altering protein synthesis without inhibiting monoamine oxidase.

Authors:  W G Tatton; J S Wadia; W Y Ju; R M Chalmers-Redman; N A Tatton
Journal:  J Neural Transm Suppl       Date:  1996

Review 8.  Modulation of gene expression rather than monoamine oxidase inhibition: (-)-deprenyl-related compounds in controlling neurodegeneration.

Authors:  W G Tatton; R M Chalmers-Redman
Journal:  Neurology       Date:  1996-12       Impact factor: 9.910

9.  Increased life expectancy resulting from addition of L-deprenyl to Madopar treatment in Parkinson's disease: a longterm study.

Authors:  W Birkmayer; J Knoll; P Riederer; M B Youdim; V Hars; J Marton
Journal:  J Neural Transm       Date:  1985       Impact factor: 3.575

10.  The effect of deprenyl and levodopa on the progression of Parkinson's disease.

Authors:  C W Olanow; R A Hauser; L Gauger; T Malapira; W Koller; J Hubble; K Bushenbark; D Lilienfeld; J Esterlitz
Journal:  Ann Neurol       Date:  1995-11       Impact factor: 10.422

View more
  5 in total

Review 1.  Pharmacological aspects of the neuroprotective effects of irreversible MAO-B inhibitors, selegiline and rasagiline, in Parkinson's disease.

Authors:  Éva Szökő; Tamás Tábi; Peter Riederer; László Vécsei; Kálmán Magyar
Journal:  J Neural Transm (Vienna)       Date:  2018-02-07       Impact factor: 3.575

2.  Selegiline reduces adiposity induced by high-fat, high-sucrose diet in male rats.

Authors:  Csilla Terézia Nagy; Gábor Koncsos; Zoltán V Varga; Tamás Baranyai; Sebestyén Tuza; Ferenc Kassai; Aliz Judit Ernyey; István Gyertyán; Kornél Király; Attila Oláh; Tamás Radovits; Béla Merkely; Nóra Bukosza; Gábor Szénási; Péter Hamar; Domokos Mathé; Krisztián Szigeti; Csilla Pelyhe; Marek Jelemenský; Zsófia Onódi; Zsuzsanna Helyes; Rainer Schulz; Zoltán Giricz; Péter Ferdinandy
Journal:  Br J Pharmacol       Date:  2018-08-07       Impact factor: 8.739

3.  Deprenyl reduces inflammation during acute SIV infection.

Authors:  K M Emanuel; K Runner; Z D Brodnik; B M Morsey; B G Lamberty; H S Johnson; A Acharya; S N Byrareddy; R A España; H S Fox; P J Gaskill
Journal:  iScience       Date:  2022-04-06

Review 4.  Selegiline: a molecule with innovative potential.

Authors:  Tamás Tábi; László Vécsei; Moussa B Youdim; Peter Riederer; Éva Szökő
Journal:  J Neural Transm (Vienna)       Date:  2019-09-27       Impact factor: 3.575

5.  Chronic Oral Selegiline Treatment Mitigates Age-Related Hearing Loss in BALB/c Mice.

Authors:  Judit Szepesy; Viktória Humli; János Farkas; Ildikó Miklya; Júlia Tímár; Tamás Tábi; Anita Gáborján; Gábor Polony; Ágnes Szirmai; László Tamás; László Köles; Elek Sylvester Vizi; Tibor Zelles
Journal:  Int J Mol Sci       Date:  2021-03-11       Impact factor: 5.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.